QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
Smaller reporting company
|
(do not check if a smaller reporting company)
|
Emerging Growth Company
|
September 30,
2021
(Unaudited)
|
December 31,
2020
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Accounts receivable
|
|
|
||||||
Investment in sales-type sublease - current
|
|
|
||||||
Other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
Other assets:
|
||||||||
Due from related parties
|
|
|
||||||
Investments in unconsolidated entities
|
|
|
||||||
Total other assets
|
|
|
||||||
Property and equipment:
|
||||||||
Operating lease right-of-use asset
|
|
|
||||||
Total property and equipment
|
|
|
||||||
TOTAL ASSETS
|
$
|
|
$
|
|
||||
LIABILITIES
|
||||||||
Current liabilities:
|
||||||||
Obligations under finance lease - current portion
|
$
|
|
$
|
|
||||
Operating lease right-of-use liability - current portion
|
|
|
||||||
Accounts payable and accrued expenses
|
|
|
||||||
Income taxes payable
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Operating lease right-of-use liability - net of current portion
|
|
|
||||||
Guarantee liability
|
|
|
||||||
Total liabilities
|
|
|
||||||
STOCKHOLDERS’ EQUITY
|
||||||||
Common stock - par value $
|
|
|
|
|||||
Additional paid-in capital
|
|
|
||||||
Retained earnings
|
|
|
||||||
Total stockholders’ equity
|
|
|
||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$
|
|
$
|
|
Three Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Revenue
|
$
|
|
$
|
|
||||
Costs and expenses:
|
||||||||
Patient expenses
|
|
|
||||||
Selling, general and administrative
|
|
|
||||||
Total
|
|
|
||||||
Operating (deficit) income
|
(
|
)
|
|
|||||
Interest expense
|
|
(
|
)
|
|||||
Interest income - sales-type sublease
|
|
|
||||||
Other income | ||||||||
Loss from investments in unconsolidated entities, net
|
(
|
)
|
(
|
)
|
||||
(Loss) income before income taxes
|
(
|
)
|
|
|||||
Provision for income taxes
|
(
|
)
|
(
|
)
|
||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
Basic and diluted net (loss) income per share
|
$
|
(
|
)
|
$
|
|
|||
Weighted average common shares outstanding
|
|
|
Nine Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Revenue
|
$
|
|
$
|
|
||||
Costs and expenses:
|
||||||||
Patient expenses
|
|
|
||||||
Selling, general and administrative
|
|
|
||||||
Total
|
|
|
||||||
Operating income
|
|
|
||||||
Interest expense
|
(
|
)
|
(
|
)
|
||||
Interest income - sales-type sublease
|
|
|
||||||
Other income | ||||||||
Loss from investments in unconsolidated entities, net
|
(
|
)
|
(
|
)
|
||||
(Loss) income before income taxes
|
(
|
)
|
|
|||||
Provision for income taxes
|
(
|
)
|
(
|
)
|
||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
Basic and diluted net (loss) income per share
|
$
|
(
|
)
|
$
|
|
|||
Weighted average common shares outstanding
|
|
|
Nine Months ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Cash flows from operating activities:
|
||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
|
||||||||
Amortization of operating lease right-of-use asset
|
|
|
||||||
Loss from investments in unconsolidated entities, net
|
|
|
||||||
Distributed earnings from unconsolidated entities
|
|
|
||||||
Deferred income taxes
|
|
(
|
)
|
|||||
Changes in:
|
||||||||
Accounts receivable
|
|
|
||||||
Income taxes payable
|
|
(
|
)
|
|||||
Other current assets
|
|
|
||||||
Accounts payable and accrued expenses
|
|
(
|
)
|
|||||
Deferred revenue
|
|
|
||||||
Operating lease right-of-use liability
|
(
|
)
|
(
|
)
|
||||
Net cash provided by operating activities
|
|
|
||||||
Cash flows from investing activities:
|
||||||||
Advances to unconsolidated entities
|
(
|
)
|
(
|
)
|
||||
Repayments from loans to unconsolidated entities
|
|
|
||||||
Capital contributions to unconsolidated entities
|
|
(
|
)
|
|||||
Principal payments received under sales-type sublease
|
|
|
||||||
Net cash provided by investing activities
|
|
|
||||||
Cash flows from financing activities:
|
||||||||
Repayment of finance lease obligations
|
(
|
)
|
(
|
)
|
||||
Net cash used in financing activities
|
(
|
)
|
(
|
)
|
||||
Net change in cash and cash equivalents
|
|
|
||||||
Cash and cash equivalents - beginning of period
|
|
|
||||||
Cash and cash equivalents - end of period
|
$
|
|
$
|
|
||||
Supplemental disclosures of cash flow information:
|
||||||||
Cash paid for:
|
||||||||
Interest
|
$
|
|
$
|
|
||||
Income taxes |
$ | $ |
Classification
|
September 30,
|
||||||||
Assets
|
2021 |
2020 |
|||||||
Current
|
|||||||||
Finance lease assets
|
Investment in sales-type sublease - current
|
$
|
|
$
|
|
||||
Long-term
|
|||||||||
Finance lease assets
|
Investment in sales-type sublease - net of current portion
|
|
|
||||||
Operating lease assets
|
Operating lease right-of-use asset
|
|
|
||||||
Total leased assets
|
$
|
|
$
|
|
|||||
Liabilities
|
|||||||||
Current
|
|||||||||
Finance lease liabilities
|
Obligations under finance lease - current portion
|
$
|
|
$
|
|
||||
Operating lease liabilities
|
Operating lease right-of-use liability - current portion
|
|
|
||||||
Long-term
|
|||||||||
Finance lease liabilities
|
Obligations under finance lease - net of current portion
|
|
|
||||||
Operating lease liabilities
|
Operating lease right-of-use liability - net of current portion
|
|
|
||||||
Total lease liabilities
|
$
|
|
$
|
|
|||||
Lease Cost
|
|||||||||
Operating lease cost
|
Selling, general and administrative
|
$
|
|
$
|
|
||||
Finance lease cost
|
|||||||||
Interest on lease liabilities
|
Interest expense
|
|
|
||||||
Sublease income
|
Interest income - sales-type sublease
|
|
|
||||||
Net lease expense (income)
|
$
|
|
$
|
(
|
)
|
Maturity of lease liabilities (as of September 30, 2021)
|
Operating lease
|
|||
2021
|
|
|||
2022
|
|
|||
2023
|
|
|||
Total
|
$
|
|
||
Less amount representing interest
|
|
|||
Present value of lease liabilities
|
$
|
|
||
Discount rate
|
|
%
|
Nine Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Patient Revenue
|
$
|
|
$
|
|
||||
Net (loss) income
|
$
|
|
$
|
|
||||
USNC’s equity in (loss) earnings of
NeuroPartners, LLC and CGK
|
$
|
(
|
)
|
$
|
|
Three Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Patient Revenue
|
$
|
|
$
|
|
||||
Net income
|
$
|
(
|
)
|
$
|
|
|||
USNC’s equity in (loss) earnings of
NeuroPartners LLC and CGK
|
$
|
(
|
)
|
$
|
|
September 30,
2021
|
December 31,
2020
|
|||||||
Current assets
|
$
|
|
$
|
|
||||
Noncurrent assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
Current liabilities
|
$
|
|
$
|
|
||||
Equity
|
|
|
||||||
Total liabilities and equity
|
$
|
|
$
|
|
Nine Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Income
|
$
|
|
$
|
|
||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
USNC’s equity in loss of FOP
|
$
|
(
|
)
|
$
|
(
|
)
|
Three Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Income
|
$
|
|
$
|
|
||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
USNC’s equity in loss of FOP
|
$
|
(
|
)
|
$
|
(
|
)
|
September 30,
2021
|
December 31,
2020
|
|||||||
Current assets
|
$
|
|
$
|
|
||||
Noncurrent assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
Current liabilities
|
$
|
|
$
|
|
||||
Noncurrent liabilities
|
|
|
||||||
Deficit
|
(
|
)
|
(
|
)
|
||||
Total liabilities and deficit
|
$
|
|
$
|
|
Nine Months Ended
September 30, |
||||||||
2021
|
2020
|
|||||||
Rental income
|
$
|
|
$
|
|
||||
Net income
|
$
|
|
$
|
|
||||
USNC’s equity in earnings of BOPRE
|
$
|
|
$
|
|
Three Months Ended
September 30, |
||||||||
2021
|
2020
|
|||||||
Rental income
|
$
|
|
$
|
|
||||
Net income
|
$
|
|
$
|
|
||||
USNC’s equity in earnings of BOPRE
|
$
|
|
$
|
|
September 30,
2021
|
December 31,
2020
|
|||||||
Current assets
|
$
|
|
$
|
|
||||
Noncurrent assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
Current liabilities
|
$
|
|
$
|
|
||||
Noncurrent liabilities
|
|
|
||||||
Equity
|
|
|
||||||
Total liabilities and equity
|
$
|
|
$
|
|
Nine Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Patient revenue
|
$
|
|
$
|
|
||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
USNC’s equity in loss of MOP
|
$
|
(
|
)
|
$
|
(
|
)
|
Three Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Patient revenue
|
$
|
|
$
|
|
||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
USNC’s equity in loss of MOP
|
$
|
(
|
)
|
$
|
(
|
)
|
September 30,
2021
|
December 31,
2020
|
|||||||
Current assets
|
$
|
|
$
|
|
||||
Noncurrent assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
Current liabilities
|
$
|
|
$
|
|
||||
Noncurrent liabilities
|
|
|
||||||
Deficit
|
(
|
)
|
(
|
)
|
||||
Total liabilities and deficit
|
$
|
|
$
|
|
Nine Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Patient revenue
|
$
|
|
$
|
|
||||
Net income (loss)
|
$
|
|
$
|
(
|
)
|
|||
USNC’s equity in earnings (loss) of CBOP
|
$
|
|
$
|
(
|
)
|
Three Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Patient revenue
|
$
|
|
$
|
|
||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
USNC’s equity in loss of CBOP
|
$
|
(
|
)
|
$
|
(
|
)
|
September 30,
2021
|
December 31, 2020
|
|||||||
Current assets
|
$
|
|
$
|
|
||||
Noncurrent assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
Current liabilities
|
$
|
|
$
|
|
||||
Noncurrent liabilities
|
|
|
||||||
Deficit
|
(
|
)
|
(
|
)
|
||||
Total liabilities and deficit
|
$
|
|
$
|
|
Item 2. |
Management Discussion and Analysis of Financial Condition and Results of Operations.
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk.
|
Item 4. |
Controls and Procedures
|
Item 1. |
Legal Proceedings
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds
|
Item 3. |
Defaults Upon Senior Securities
|
Item 4. |
Submission of Matters to a Vote of Security Holders
|
Item 5. |
Other Information
|
Item 6. |
Exhibits
|
Certification of President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.
|
|
Certification of President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.
|
|
101
|
Interactive Data Files providing financial information from the Registrant’s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 in XBRL (eXtensible Business Reporting Language). Pursuant
to Regulation 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the
Securities Exchange Act of 1934, as amended, and are otherwise not subject to liability.
|
U.S. NeuroSurgical Holdings, Inc.
|
|
(Registrant)
|
Date: November 19, 2021
|
By:
|
/s/ Alan Gold
|
|
Alan Gold
|
|||
Director, President and
|
|||
Chief Executive Officer
|
|||
and
|
|||
Principal Financial Officer
|
|||
of the Registrant
|
1. |
I have reviewed this Report on Form 10-Q of U.S. NeuroSurgical Holdings, Inc.;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;
|
4. |
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and
15d–15(f)) for the registrant and have:
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
|
d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and;
|
5. |
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: November 19, 2021
|
/s/ Alan Gold
|
|
Alan Gold
|
||
President & Chairman of the Board
|
||
(Principal Executive Officer
|
||
and Principal Financial Officer)
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of U.S. NeuroSurgical Holdings, Inc.
|
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares |
Sep. 30, 2021 |
Dec. 31, 2020 |
---|---|---|
STOCKHOLDERS' EQUITY | ||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 25,000,000 | 25,000,000 |
Common stock, shares issued (in shares) | 7,792,185 | 7,792,185 |
Common stock, shares outstanding (in shares) | 7,792,185 | 7,792,185 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] | ||||
Revenue | $ 0 | $ 662,000 | $ 1,061,000 | $ 2,005,000 |
Costs and expenses: | ||||
Patient expenses | 0 | 81,000 | 86,000 | 276,000 |
Selling, general and administrative | 268,000 | 297,000 | 815,000 | 941,000 |
Total | 268,000 | 378,000 | 901,000 | 1,217,000 |
Operating (deficit) income | (268,000) | 284,000 | 160,000 | 788,000 |
Interest expense | 0 | (5,000) | (3,000) | (24,000) |
Interest income - sales-type sublease | 0 | 16,000 | 8,000 | 60,000 |
Other income | 9,000 | 0 | 9,000 | 0 |
Loss from investments in unconsolidated entities, net | (77,000) | (56,000) | (350,000) | (292,000) |
(Loss) income before income taxes | (336,000) | 239,000 | (176,000) | 532,000 |
Provision for income taxes | (8,000) | (75,000) | (202,000) | (148,000) |
Net (loss) income | $ (344,000) | $ 164,000 | $ (378,000) | $ 384,000 |
Basic net (loss) income per share (in dollars per share) | $ (0.04) | $ 0.02 | $ (0.05) | $ 0.05 |
Diluted net (loss) income per share (in dollars per share) | $ (0.04) | $ 0.02 | $ (0.05) | $ 0.05 |
Weighted average common shares outstanding (in shares) | 7,792,185 | 7,792,185 | 7,792,185 | 7,792,185 |
Basis of Preparation |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of Preparation [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of Preparation |
Note A - Basis of Preparation
The accompanying Condensed Consolidated Financial
Statements of U.S. NeuroSurgical Holdings, Inc. and Subsidiaries (the “Company”) as of September 30, 2021, and 2020, are unaudited. However, in the opinion of management, such statements include all adjustments necessary for a fair
statement of the information presented therein. The Consolidated Balance Sheet at December 31, 2020 has been derived from the audited Consolidated Financial Statements at that date appearing in the Company’s Annual Report on Form 10-K.
Pursuant to accounting requirements of the Securities
and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying Condensed Consolidated Financial Statements and notes do not include all disclosures required by accounting principles generally accepted in the United
States of America for complete financial statements. Accordingly, these statements should be read in conjunction with the Company’s most recent annual Consolidated Financial Statements.
Consolidated results of operations for interim
periods are not necessarily indicative of those to be achieved for full fiscal years. The only change to the Company’s equity in the nine months ended September 30, 2021 and 2020 was net income or loss for the periods.
In May 2014, the Financial Accounting Standards Board
(the “FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (“Topic 606”), amending existing revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature,
amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Topic 606 defines a five-step process to accomplish this objective, including identifying the contract with the customer and the performance
obligations within the contract, determining the transaction price including estimates of any variable consideration, allocating the transaction price to each separate performance obligation, and recognizing revenue as the company
satisfies the performance obligation. We adopted the provisions of Topic 606 as of January 1, 2018, on a modified retrospective basis and applied it to the Company’s sole contract at the date of adoption. We concluded that the impact to
the manner in which we recognize revenue is immaterial. Our revenue is primarily generated from a leasing arrangement with New York University (“NYU”), which is not within the scope of Topic 606, and from the sale of maintenance services
with a single performance obligation, under which revenue is recognized in a similar manner as compared to the method under the prior revenue standards. The Company recognizes maintenance income ratably over time as patient procedures are
performed.
Prior to October 2018, the Company’s agreement with
NYU primarily consisted of an operating lease, and the associated patient revenue from the use of the gamma knife was primarily operating lease income. In October 2018, the agreement was reevaluated to be a sales-type sublease between
the Company, the lessor, and NYU, the lessee. The present value of all fixed future minimum lease payments payable by NYU to the Company were recorded as an investment in sublease effective October 1, 2018. The patient revenue under
the tiered schedule was considered contingent income and had been recognized on a systematic basis using an average fee per procedure.
We adopted the provisions of ASU 2016-02, Leases
(“Topic 842”), as amended, as of January 1, 2019. The adoption of Topic 842 had a material impact on the Company’s Consolidated Balance Sheets due to the recognition of certain right-of-use (“ROU”) assets and lease liabilities. Although
a significant amount of our revenue is now accounted for under Topic 842, this guidance did not have a material impact on our Consolidated Statements of Operations or Cash Flows. Because of the transition method we used to adopt Topic
842, Topic 842 will not be applied to periods prior to adoption and the adoption of Topic 842 had no impact on our previously reported results, or on opening equity at January 1, 2019.
The tables below present financial information
associated with our leases.
|
Gamma Knife at NYU Medical Center |
9 Months Ended |
---|---|
Sep. 30, 2021 | |
Gamma Knife at NYU Medical Center [Abstract] | |
Gamma Knife at NYU Medical Center |
Note B – Gamma Knife at
NYU Medical Center
U.S. NeuroSurgical, Inc. (“USN”), a wholly-owned subsidiary of U.S. NeuroSurgical Holdings, Inc., opened a New York gamma knife treatment center in July 1997 on the campus of New York University (“NYU”) Medical Center. The Company’s
contract with NYU, its only customer, ended in March 2021. Upon termination of the NYU contract, the Company recognized a gain of $100,000
relating to previously accrued expenses. This gain was included as a reduction in selling, general and administrative expense in the quarter ended March 31, 2021. The Company is actively seeking new business ventures and believes that its cash
reserves, which approximate $2.6 million at September 30, 2021, will allow the Company the opportunity do so. Such plans include
possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations. In addition to these activities, the Company has been
exploring possible combinations with other existing businesses that would create a larger operating entity that would better justify the expenses involved in continuing as an independent publicly traded company.
|
The Southern California Regional Gamma Knife Center |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Southern California Regional Gamma Knife Center [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Southern California Regional Gamma Knife Center |
Note C – The Southern California Regional Gamma
Knife Center
During 2007, the Company, through a noncontrolling
interest in joint ventures, managed the formation of the Southern California Regional Gamma Knife Center at San Antonio Regional Hospital (“SARH”) in Upland, California. Corona Gamma Knife, LLC (“CGK”) is party to a 14-year agreement with SARH to renovate space in the hospital and install and operate a Leksell PERFEXION gamma knife. CGK leases the gamma
knife from NeuroPartners LLC, which holds the gamma knife equipment. In addition to returns on its ownership interests, USNC expects to receive fees for management services relating to the facility.
USNC is a 20% owner of NeuroPartners LLC and owns 39% of CGK.
USNC was a 20% guarantor on NeuroPartners LLC’s seven-year lease
with respect to the gamma knife equipment and certain leasehold improvements at SARH. In February 2016, NeuroPartners LLC negotiated a new five-year
lease to fund the reloading of cobalt and related construction services. The new lease of $1,663,000 included a balance of $668,000 from the prior lease obligations. This new lease was payable over 60 months. The first payment of $31,000 was paid in April 2016 and
the final payment was paid in March 2021.
Construction of the SARH gamma knife center was
completed in December 2008 and the first patient was treated in January 2009. The project has been funded principally by outside investors. While the Company, through its joint ventures, has led the effort in organizing the business and
overseeing the development and operation of the SARH center, its investment to date in the SARH center has been minimal.
At September 30, 2021 and December 31, 2020, the
Company’s combined recorded investment of NeuroPartners LLC and CGK was $4,000 and $26,000, respectively. For the nine months ended September 30, 2021, the Company’s combined equity in loss of NeuroPartners LLC and CGK was $22,000 compared to combined equity in earnings of $134,000 for the nine months ended September 30, 2020. At September 30, 2021 and December 31, 2020, amounts due from related parties was $0 and $9,000, respectively.
The following tables present the aggregation of
summarized financial information of NeuroPartners LLC and CGK:
NeuroPartners LLC and CGK Condensed
Combined Income Statement Information
NeuroPartners LLC and CGK Condensed Combined Balance
Sheet Information
|
Florida Oncology Partners |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Florida Oncology Partners [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Florida Oncology Partners |
Note D – Florida Oncology Partners
During 2010, through the formation of a joint
venture, in which it has a noncontrolling interest, the Company expanded its market strategy to include opportunities to develop cancer centers featuring radiation therapy. These centers utilize linear accelerators with Intensity
Modulated Radiation Therapy (“IMRT”) and Image Guided Radiation Therapy (“IGRT”) capabilities. In 2010, the Company formed Florida Oncology Partners, LLC (“FOP”) in partnership with local physicians and other investors. USNC owns a 24% interest in the venture. FOP’s first center was located in Miami, Florida and opened in the second quarter of 2011.
During 2011, FOP entered into a seven-year capital lease with Key Bank for $5,800,000.
Under the terms of the capital lease, USN agreed to guarantee a maximum of $1,433,000, approximately 25% of the original lease obligation in the event of default. USN was a guarantor jointly with most of the other members of FOP. The
guarantee was eliminated upon repayment of the outstanding lease balance in May 2018.
In December 2015, FOP entered into an agreement with
21st Century Oncology for the sale of FOP’s Varian Rapid Arc linear accelerator and other medical equipment at the FOP location. 21st Century Oncology paid FOP $1,000,000 as a down payment for the equipment and agreed to make monthly payments of $172,000 for the equipment and all monthly payments due under the equipment lease with Key Bank. As of this date, 21st Century Oncology has not satisfied all of the terms of the agreement. In May 2017,
21st Century Oncology filed for Chapter 11 bankruptcy protection and FOP was listed as an unsecured creditor. As a result, since June 2017, FOP has not received the agreed rental payments beyond the monthly payments for the equipment
lease. As noted above, the equipment lease was repaid in May 2018 and title to the equipment was transferred to 21st Century Oncology. In December 2018, FOP was awarded 10,820 shares of 21st Century Oncology Holdings Inc. common stock as part of the bankruptcy proceedings. The title to these shares was transferred to USNC during
2020. The market value of these shares is unclear at this time as there is no readily available market for them, and accordingly, no value has been recorded for these shares at September 30, 2021 by USNC. During the year ended December
31, 2020, FOP received a payment of approximately $158,000 from 21st Century Oncology. FOP used these funds to repay $155,000 of previous advances from USNC. FOP will continue to monitor the impact of 21st Century Oncology’s bankruptcy and pursue amounts that
it is owed. However, there can be no assurance that FOP will be successful in these efforts.
Late in 2016, FOP took initial steps toward the
development of a new radiation therapy center in Homestead, Florida. In December 2016, FOP entered into a ten-year lease
agreement for office space located at 20405 Old Cutler Towne Center. FOP had to deliver an $88,000 letter of credit in
conjunction with this office lease which collateral is being held in a restricted certificate of deposit. FOP began incurring architecture costs for planning/refitting the new space. During the first half of 2017, a financing agreement
with BB&T Bank for the medical equipment and leasehold improvements was negotiated and then signed on August 31, 2017. In November 2017, the amounts for the equipment and leasehold improvements costs were finalized and paid under
this financing agreement for a total loan of $4,106,000 to be paid over seven years. Under the terms of the financing agreement, USN agreed to guarantee the amount initially borrowed. USN is the guarantor with several other members of
FOP. The outstanding balance on the financing facility was $2,819,000 at September 30, 2021 and $3,066,000 at December 31, 2020. Effective November 15, 2019, FOP transferred this loan, along with the equipment acquired with the loan
proceeds, to CB Oncology Partners, LLC (“CBOP”.) The Company expects any potential liability from this guarantee to be reduced by the recoveries of the respective collateral. Late in the third quarter of 2017, it was determined that the
business opportunity at this new location should be pursued by a different investor group, and FOP arranged to sell the opportunity to this group. CBOP was organized on September 1, 2017, to acquire the assets and rights in this new
center from FOP.
In June 2017, FOP entered into an agreement with a
third-party owner of a radiation therapy center located in Miami, Florida, whereby FOP took over the operation of the center effective September 22, 2017, for a ten-year initial term, and up to three additional
terms of five years each. This agreement was accounted for as a capital lease and, accordingly, FOP recorded assets and
capital lease liabilities totaling $14,321,000 at September 22, 2017. The lease required monthly payments in the first year of
$160,000, increasing by 2%
each year; currently the payment is $170,000. FOP abandoned its operations at this radiation center on June 28, 2019 due to
continued losses at the site and lack of success in good faith efforts to renegotiate the agreement after several months of discussion. FOP could be considered in default of the agreement and the third-party owner could pursue action
against FOP. Due to the circumstances, FOP derecognized the associated assets and liabilities and calculated a contingent liability equal to the net liabilities derecognized. FOP has not, however, been released from its contractual
obligation to the third-party owner. At September 30, 2021, FOP was obligated to make a further $17.6 million of lease
payments for the period from July 2019 to September 2027, with no payments made since June 2019. Due to abandoning the
operations of the Miami center as well as continued working capital deficits, FOP has filed dissolution papers to permanently cease operations in the state of Florida. In addition, FOP is seeking relief from this obligation due to the
millions of dollars of deficit FOP is carrying.
The Company’s recorded investment in FOP at September
30, 2021 and December 31, 2020 has been reduced to zero due to losses incurred in prior years. No equity in earnings has been recorded by the Company for the nine months ended September 30, 2021, and 2020, due to FOP’s deficit at
September 30, 2021, and September 30, 2020.
During the year ended December 31, 2020, the Company
wrote off all amounts due from FOP and accrued interest thereon. The Company recorded amounts written off and increases in the allowances as a component of loss from investments in unconsolidated entities and as a deduction in interest
income for interest earned.
Because of loans made to FOP, FOP is considered a
variable interest entity of the Company. However, as the Company is not deemed to be the primary beneficiary of FOP, since it does not have the power to direct the operating activities that most significantly affect FOP’s economic
performance, the entity is not consolidated, but certain disclosures are provided herein.
The following tables present the summarized financial
information of FOP:
FOP Condensed Income Statement
Information
FOP Condensed Balance Sheet Information
|
Boca Oncology Partners |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Boca Oncology Partners [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Boca Oncology Partners |
Note E – Boca Oncology Partners
During the quarter ended June 30, 2011, the Company,
through the formation of a joint venture, in which it had a noncontrolling interest, participated in the formation of Boca Oncology Partners, LLC (“BOP”), for the purpose of owning and operating a cancer center in Boca Raton, Florida. In
June 2011, Boca Oncology Partners RE, LLC (“BOPRE”,) an affiliated entity, purchased a 20% interest in Boca West IMP, owner of
a medical office building in West Boca, Florida in which BOP operates. BOP occupies 6,000 square feet of the 32,000 square foot building. The Company invested $225,000 initially and had a 22.5% interest in BOP and BOPRE. In
February 2014, the Company and other members sold their interests in BOP.
In June 2012, BOPRE purchased an additional 3.75% of Boca West IMP from another investor bringing its total interest to 23.75%. BOPRE accounts for this investment under the cost method since it does not exercise significant influence over Boca West, IMP.
During the years ended December 31, 2018 and 2017,
several investors relinquished part of their ownership interest in BOPRE, and those interests were distributed among the remaining investors in relationship to their percentages owned. As a result, the Company now holds a 21.22% ownership interest in BOPRE, which it accounts for under the equity method. The Company’s recorded investment in BOPRE is $149,000 and $134,000 at
September 30, 2021 and December 31, 2020, respectively
USNC was a 10% guarantor of 50% of the outstanding balance of
Boca West IMP’s ten-year mortgage. This mortgage had an original balance of $3,000,000 and is secured by the medical office building in which BOP operates. In April 2020, the partners of Boca West IMP refinanced the mortgage in order to
recover some of the cash that was invested before the building was completely occupied and removed USNC as a guarantor.
The following tables present the summarized financial
information of BOPRE:
BOPRE Condensed
Income Statement Information
BOPRE Condensed Balance Sheet Information
|
Medical Oncology Partners |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Oncology Partners [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Oncology Partners |
Note F - Medical Oncology Partners
In April 2015, Medical Oncology Partners, LLC
(“MOP”,) was formed in partnership with local physicians and other investors. MOP was established to acquire a 100% equity
interest in United Oncology Medical Associates of Florida, LLC (“UOMA”.) USNC was not a member of MOP at the time of formation as it was not able to participate due to the fact that USNC was not a physician. Nevertheless, USNC wished to
eventually obtain an equity interest in MOP and loaned Dr. Jaime Lozano, the principal investor in MOP and a co-investor in FOP, $173,000.
Dr. Lozano used these funds, along with an equal amount of his own funds (a total of $345,000), to purchase a 76.67% interest in MOP. Other investors paid a further $105,000 for the remaining equity in MOP. MOP used the $450,000 of
financing to acquire a 100% equity interest in UOMA. An application was filed for a waiver to allow USNC to hold an equity
interest notwithstanding the physician requirement and on December 22, 2016, USNC was cleared to become a part owner of MOP. Dr. Lozano agreed to exchange half of his membership interest to USNC in settlement of the note to USNC. USNC
and Dr. Lozano also agreed to share equally in providing a 5% equity interest in MOP to an additional investor as a consulting
fee for services rendered in the administration of MOP and UOMA. At December 22, 2016, USNC owned 35.83% of MOP with an
initial carrying value of $161,000. The Company recorded its share of losses of $12,000 for the period from December 22, 2016 to December 31, 2016, against its investment which resulted in a reduction of its equity investment to $149,000.
Due to increasing costs, continued net losses since
April 2015, and reliance on related party and other debt for operating cash flows, the fair value of UOMA is less than its carrying amount. The Company tested its investment for impairment at December 31, 2016 and determined that the
investment was impaired, and an impairment loss was recorded against the entire equity balance in MOP, as well as loans from USN and USNC to MOP and UOMA. For the nine months ended September 30, 2021 and 2020, the Company’s equity in loss
of MOP was $100,000 and $373,000,
respectively, but was not recorded due to prior losses.
During the year ended December 31, 2020, the Company
wrote off all remaining amounts due from MOP and UOMA and accrued interest thereon, resulting in a $686,000 loss. Increases in
allowances and amounts written off have been recorded as losses from investments in unconsolidated entities. During the nine months ended September 30, 2021, the Company advanced an additional $342,000, all of which has been fully impaired. These allowances and write offs were recorded as losses from investments in unconsolidated entities.
Due to loans made to MOP and UOMA, MOP and UOMA are
considered to be variable interest entities of the Company. However, as the Company is not deemed to be the primary beneficiary of MOP or UOMA, since it does not have the power to direct the operating activities that most significantly
affect MOP’s or UOMA’s economic performance, the entities are not consolidated, but certain disclosures are provided herein.
The following table presents the summarized financial
information of MOP:
MOP Condensed Consolidated Income Statement
Information
MOP Condensed Consolidated Balance Sheet Information
|
CB Oncology Partners |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CB Oncology Partners [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CB Oncology Partners |
Note G - CB Oncology Partners
CBOP was organized September 1, 2017, to acquire the
rights of the new center from FOP. USNC originally had a 24% equity interest in CBOP. Beginning in October of 2017, CBOP
began paying the remainder of the costs associated with opening the center. The medical center opened and treated its first patient in January of 2018.
Effective November 15, 2019, FOP transferred to, and
CBOP assumed, a loan with BB&T bank, that it had entered into in order to finance the purchase of equipment and build out of the new center, as well as the associated property and equipment. In addition, CBOP and BB&T agreed to
reduce the monthly loan repayments for the next nine months, and to extend the term of the loan from November 2024 to July 2025. In July 2020 CBOP and BB&T further agreed to reduce the monthly payments for the life of the loan and
extended the loan to July of 2027.
In June 2020, CBOP made a $500,000 capital call to its members. UNSC converted previously-made advances totaling $121,000 into equity in CBOP to meet its capital requirement, and other members contributed $212,000 in cash. The remaining capital contributions are not expected to be met and, accordingly, the Company’s equity interest in CBOP increased to 28.58% in June 2020.
Amounts due from CBOP at September 30, 2021, total $2,165,000 of outstanding principal, less $1,251,000
of allowances, for a net receivable of $914,000 all of which is included in due from related parties on the accompanying
Condensed Consolidated Balance Sheet. At December 31, 2020, CBOP owed the Company $2,154,000 of which $1,251,000 had been reserved for a net receivable of $903,000 all of which is included in due from related parties on the accompanying Condensed Consolidated Balance Sheet. These balances accrue interest at 6% per annum. Interest earned by the Company from the amounts owed by CBOP totaled $93,000 and $94,000 for the nine months ended September
30, 2021, and 2020, respectively. At September 30, 2021 and December 31, 2020, total accrued interest was $366,000 and $273,000, respectively, all of which has been fully reserved for. The Company records increases in the allowance, when applicable, as a
component of loss from investments in unconsolidated entities and as a deduction in interest income for interest earned.
Due to loans made to CBOP, CBOP is considered to be a
variable interest entity of the Company. However, as the Company is not deemed to be the primary beneficiary of CBOP, since it does not have the power to direct the operating activities that most significantly affect CBOP’s economic
performance, the entity is not consolidated, but certain disclosures are provided herein.
The following table presents the summarized financial
information of CBOP:
CBOP Condensed Income Statement Information
CBOP Condensed Balance Sheet Information
|
Income Taxes |
9 Months Ended |
---|---|
Sep. 30, 2021 | |
Income Taxes [Abstract] | |
Income Taxes |
Note H – Income Taxes
The Company’s income tax rate, which includes federal and state income taxes, was approximately 115%, for the
nine months ended September 30, 2021, and 28% for the nine months ended September 30, 2020. The Company recorded a tax charge of $202,000 and $148,000 for the nine
months ended September 30, 2021, and 2020, respectively. The higher income tax expense in 2021 is primarily due to the annualized effect of the NYU contract ending in March 2021, including the catch-up tax effects of a cash basis taxpayer with no
operations, and the tax effect of a valuation allowance expected to be necessary for any deferred tax asset at the end of the year.
|
Subsequent Event |
9 Months Ended |
---|---|
Sep. 30, 2021 | |
Subsequent Event [Abstract] | |
Subsequent Event |
Note I – Subsequent
Event
Acquisition of Elite Health Plan, Inc. Effective October 1, 2021, USN, the Company’s wholly-owned subsidiary, acquired all of the outstanding shares of capital stock of Elite Health Plan, Inc.,
a California corporation (“Elite Health”) and, in exchange therefor, the former holders of Elite Health were issued newly-issued shares of USN, which following the transaction represent 15% of the outstanding shares of USN. Elite Health currently has no revenue and will not be in a position to generate revenue for an indefinite period while it seeks to
obtain a license to operate a Medicare Advantage Plan in California. The plan for the development and growth of Elite Health will require the investment of significant time and financial resources. The success of Elite Health will depend on
obtaining all necessary approvals and gaining access to a competent network of providers and enrolling a critical level of subscribers. We are still evaluating the impacts from this transaction to our consolidated financial statements.
|
Basis of Preparation (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of Preparation [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Information Associated with our Leases |
The tables below present financial information
associated with our leases.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity of Lease Liabilities |
|
The Southern California Regional Gamma Knife Center (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neuro Partners LLC and CGK [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Equity Method Investments [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment Summarized Financial Information |
The following tables present the aggregation of
summarized financial information of NeuroPartners LLC and CGK:
NeuroPartners LLC and CGK Condensed
Combined Income Statement Information
NeuroPartners LLC and CGK Condensed Combined Balance
Sheet Information
|
Florida Oncology Partners (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FOP [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Equity Method Investments [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment Summarized Financial Information |
The following tables present the summarized financial
information of FOP:
FOP Condensed Income Statement
Information
FOP Condensed Balance Sheet Information
|
Boca Oncology Partners (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Equity Method Investments [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment Summarized Financial Information |
The following tables present the summarized financial
information of BOPRE:
BOPRE Condensed
Income Statement Information
BOPRE Condensed Balance Sheet Information
|
Medical Oncology Partners (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Oncology Partners LLC [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Equity Method Investments [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment Summarized Financial Information |
The following table presents the summarized financial
information of MOP:
MOP Condensed Consolidated Income Statement
Information
MOP Condensed Consolidated Balance Sheet Information
|
CB Oncology Partners (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CB Oncology Partners LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Equity Method Investments [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment Summarized Financial Information |
The following table presents the summarized financial
information of CBOP:
CBOP Condensed Income Statement Information
CBOP Condensed Balance Sheet Information
|
Gamma Knife at NYU Medical Center (Details) - NYU [Member] |
9 Months Ended |
---|---|
Sep. 30, 2021
USD ($)
| |
Gamma Knives at NYU Medical Center [Abstract] | |
Gain on termination of contract | $ 100,000 |
Minimum [Member] | |
Gamma Knives at NYU Medical Center [Abstract] | |
Cash reserves | $ 2,600,000 |
Income Taxes (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
|
Income Taxes [Abstract] | ||||
Federal and state income taxes, rate | 115.00% | 28.00% | ||
Tax charge | $ 8,000 | $ 75,000 | $ 202,000 | $ 148,000 |
Subsequent Event (Details) |
1 Months Ended |
---|---|
Oct. 19, 2021 | |
Subsequent Event [Member] | Elite Health Plan, Inc. [Member] | |
Subsequent Event [Abstract] | |
Equity consideration, percentage of outstanding shares | 15.00% |
2&K1PH,HK[
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M<<9J[!.'6:JR1V52&"4UNM#AMVP6KGL?U!+ P04
M " O@'-32E!YVX $ !L"0 & 'AL+W=OVBUDDC8(Y^16E2$0U2ET1C'=7J-)$NYT+#;ZCYDXO7M?="55I8:[X8>^6A=
MZ'54)J?/(2(/4(T"?;+R!*V%8M8Z51N<@0CJ^ 7C8^X)F)+9[J#@ APXMK%7
MKBO7)%[CR?[X#CP1R4U--_5;N<'45$G;PB,9Y1N!E],'>51>TOY MN0HM/H+
M+:67N4 ;0B.7M\[
VN>G[:53=9
M#TN&J/N^ZV&I#86IK8JW]@M@@EP>\^Q /5*)9PYTSH[V,L(WYHA4 $-HQ=%9
M];0ZAKTSAX^OGD_BFVEQF&K-%&>[CYAOJ-H/I&2M3$;7?149+XY+BQO)=N8
M<<&D9)FYW!*L-@]:0+U?,R9/-]I!=6@]_@]02P,$% @ +X!S4ZF5F\12
M @ O@4 !D !X;"]W;W)K$-)OA?0O"IDSR40MSI3X%>2@A1S\EUP.6[[AQ1"F
MU)0X+ QH)#R5N>%?F8L'IU(7'O64 +WQD\-@46IIF_9J3]OA-&YZ\H]Y,]GF
M5&^8-(1#@:Y19XA5T,VT:#965;Y#U\IBO_MEB0,6M#/ ^T(I>]@X@G9DI[\!
M4$L#!!0 ( "^
1RR[F
M^/28T0U@.5IHRS\4!5%(BQ1&:5Z[(\[$MY&0XZ?C)0$C4=-+PE+0P7$D'H
463>I8C88
M?F0] A7)P,CJ^:6L/ #75[K]%N4(/ NLUM8M;]'<#4%Q%K235A5"/DWB!3%4
M*/W:Q Y'1R5)-U:3J^18(XF[GF7C*%Z$=F*\H6PF@( LJ"P2%VO"2,;I=HRZ
MG(];K"+\Q?/^9>L!%6TA[WWKV*^UP9VT>I9D(<5GR,YG98.;/+^X4P#!G"X.
M0